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Thomas A. Shuster, DO, W. Ray Silliman, MD, Richard D. Coats, MD, Leila Mureebe, MD, and Donald
Silver, MD, Columbia, Miss
Objective: To determine the current frequency, types of patients, indications for testing, morbidity and mortality, and
management of heparin-induced thrombocytopenia (HIT).
Methods: Between December 1998 and July 2001, the charts of 102 inpatients that tested positive for heparin-associated
antiplatelet antibodies (HAAb) were reviewed. There were 33,941 inpatients, 10,348 of them having received unfrac-
tionated or low molecular weight heparins. HAAb were determined by platelet aggregometry.
Results: There were 58 males and 44 females with a mean age of 56 years. The majority (72%) of patients were admitted
to a surgical service (23% were admitted to medicine, and 5% were admitted to obstetrics/pediatrics). Indications for
testing included one or more low platelet counts (n  51), unexplained arterial (n  33) or venous (n  6) thromboses,
resistance to anticoagulation (n  1), prior history of HAAb (n  3), organ transplant (n  17), or other indication (n
 4). The HAAb “patterns” were variable, with patients having antibodies only to bovine (n  7) or porcine heparin (n
 5), bovine and porcine heparins (n  17), enoxaparin (n  3), fragmin (n  7), or all 4 heparins (n  43). The
HIT-related mortality was 6.9%, and the morbidity was 30% with 19 arterial and 7 venous thromboses and 5 bleeding
events. Management consisted of discontinuation of heparin in 95 patients. Twenty-five patients did not require
continued anticoagulation. When needed, anticoagulation was continued with a direct thrombin inhibitor (n  32),
enoxaparin (n  16), warfarin (n  15), or aspirin (n  7). Seven patients continued to receive unfractionated heparin
(n  4) or low molecular weight heparin (n  3).
Conclusions: HIT occurs in 0.99% of inpatients receiving heparin and remains an important nondiscriminatory contrib-
utor to their morbidity and mortality. Patients receiving any form of heparin who develop a decreasing platelet count,
unexplained thrombosis, or resistance to heparin anticoagulation should be tested for HAAb. If HAAb are detected,
patients must not receive the sensitizing heparin(s). (J Vasc Surg 2003;38:1316-22.)
The description of the heparin-induced thrombocyto-
penia syndrome (HIT) in 1973 provided insight into the
problem of patients who developed thromboses while an-
ticoagulated with heparin.1 An immune basis for HIT was
established in 1977.2 All forms of heparin can be immuno-
genic.3 It has been noted that the early, very high mortality
and morbidity of HIT, 23% and 61%, respectively, could be
dramatically reduced to 1.1% and 7.4%, respectively, with
prompt recognition of the syndrome and cessation of ad-
ministration of the sensitizing heparin(s) to patients with
heparin-associated antiplatelet antibodies (HAAb).4,5
This study was undertaken to determine the current
incidence, types of patients, indications for testing, morbid-
ity and mortality, and management of HIT. Our hypothesis
was that the incidence is increasing while the mortality and
morbidity of HIT has continued to decrease. We also
wished to evaluate the role of heparin alternatives, specifi-
cally direct thrombin inhibitors, in the current manage-
ment of HIT.
METHODS AND MATERIAL
After receiving approval by our Institutional Review
Board, the charts of 102 consecutive patients who tested
positive for HAAb between December 1, 1998 and July 30,
2001 were reviewed. Information collected included age,
sex, admission service and diagnosis, morbidity and mor-
tality, platelet counts, indications for antibody testing, type
of antibodies detected, and management.
Data collected for the same period from our hospital
database included hospital admissions, mortality, and the
frequency of administration of unfractionated heparin
(UH), low molecular weight heparin (LMWH), and lepi-
rudin. These data were compared to national data regard-
ing hospital admissions over the years 1998, 1999, 2000,
and adjusted for the year 2001.6
Our method of platelet aggregation for the detection of
HAAb has been described previously.7 Briefly, platelet-rich
plasma (PRP) from healthy donors and platelet-poor
plasma (PPP) from study patients are prepared by means of
differential centrifugation of whole blood collected in 3.8%
citrate. The PRP (0.1 ml) and PPP (0.15 ml) are combined
and incubated for 3 minutes at 37°C. This mixture is
further incubated for an additional 25 minutes in a platelet
aggregometer with 25 L of 1 of the following 4 sources of
heparin: porcine intestinal mucosa heparin (Solopak Labo-
ratoreies, Elk Grove, Ill), bovine lung heparin (Upjohn
Company, Kalamazoo, Mich), enoxaparin (Lovenox;
Rhone-Poulenc Rorer Pharmaceuticals, Inc, Collegeville,
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Pa), and dalteparin (Fragmin; Vetter Pharma-Ferrigung,
Ravensburg, Germany) to a final concentration of 1 unit of
each heparin per milliliter. Platelet aggregation is measured
with a 4-channel aggregometer (Chronolog Corporation,
Havertown, Penn). Lag time, slope of the aggregation
curve, and time to aggregation are recorded. Aggregation is
defined as a greater than 20% change in optical density.
Aggregation is confirmed by visual inspection.7,8
If aggregation does not occur, 25 L of adenosine
diphosphate (105 mol/L) is added to ensure the proper
reactivity of the donor PRP. If aggregation occurs, the
plasma is retested with high-dose heparin (0.025 mL of
1000 U/mL, final concentration of 100 U/mL of each
heparin) to eliminate false-positive results caused by non-
specific binding between heparin and platelets.8,9
Platelet counts were determined in the central hospital
laboratory with an automated blood cell counter (Coulter
Maxm; Coulter Corporation, Miami, Fl). Thrombocytope-
nia was defined as a platelet count of less than 100,000/
mm3, a decrease in platelet count of more than 30% in
consecutive samples, or a progressively decreasing platelet
count.
Patients who developed thrombocytopenia, resistance
to anticoagulation with heparin, or thrombotic events
while receiving heparin were suspected of having HIT. The
diagnosis of HIT was confirmed by resolution of thrombo-
cytopenia after cessation of heparin administration, the
exclusion of other causes for the thrombocytopenia, and in
all patients a positive heparin-induced platelet aggregation
assay.8 Patients who test negative are retested daily up to 96
hours to ensure negativity.
RESULTS
HAAb were identified by platelet aggregation studies in
102 inpatients. There were 58 males and 44 females with an
average age of 56.1 years (3 weeks to 83 years). During the
period from December 1, 1998 to July 30, 2000, there
were 33,941 inpatients and 30% of them (n  10348)
received some form of heparin. The 102 patients with
HAAb represent 0.30% of the 33,941 inpatients. HAAb
occurred in 0.99% (102 of 10,348) of patients receiving
heparin. Overall, 7256 patients received only UH and 67
(0.92%) of them developed HAAb. LMWH was adminis-
tered to 1339 patients, and 21 of them (1.6%) produced
HAAb. Seven (0.4%) of the 1753 patients receiving both
UH and LMWH produced HAAb. Seven patients with
prior exposure to unknown types of heparin were trans-
ferred to our hospital, met criteria for testing, and tested
positive for HAAb.
Indications for HAAb testing are presented in Table I.
The most common indications were a decreasing platelet
count (45%, Fig 1) and arterial thrombosis (26.5%). The
indications for heparin administration (Table II) included
deep venous thrombosis (DVT) prophylaxis (36%), vascu-
lar surgery (21.5%), open heart surgery (18.6%), and dial-
ysis (7.8%). The admitting service was predominately sur-
gical (n 73, 72% of patients with HAAb), with the largest
single group of patients (n  28) admitted to the vascular
surgery service. Other admitting services are outlined in
Table III.
The 102 patients with HIT had a mortality of 6.9% (n
 7) and were responsible for 0.76% (7 of 922) of our
in-hospital deaths during the study period. The total inpa-
tient mortality in our hospital was 2.7%. The inpatient
Fig 1. Platelet counts at time of testing and nadir.
Table II. Indications for anticoagulation
Indication No. %
DVT prophylaxis 37 36.3%
Vascular surgery 22 21.5%
Cardiac surgery 19 18.6%
Dialysis 8 7.8%
DVT treatment 2 1.9%
Angioplasty 2 1.9%
Warfarin conversion 2 1.9%
Atrial fibrillation 1 0.9%
Total parental nutrition 1 0.9%
Thrombolysis 1 0.9%
Unknown* 7 7.0%
DVT, Deep venous thrombosis.
*Seven patients received an unknown type of heparin prior to admission to
our hospital.
Table I. Indications for HAAb testing
Indication Patients* %
Decreasing platelet count 51 44.7%
Arterial thrombosis 30 26.5%
Organ transplant 17 15.0%
Deep venous thrombosis 2 1.8%
Pulmonary embolism 2 1.8%
Transient ischemic attack 3 2.6%
History of HAAb 3 2.6%
Thrombosed dialysis catheter 2 1.8%
Heart transplant 2 1.8%
Miscarriage 1 0.8%
Resistance to anticoagulation 1 0.8%
HAAG, Heparin-associated antiplatelet antibodies.
*Seven patients received an unknown type of heparin prior to admission to
our hospital.
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mortality while receiving a single agent, either UH or
LMWH, was 5.4% and 3.0%, respectively. Our inpatient
hospital mortality for patient receiving 2 agents, both UH
and LMWH, was 8.4%. The inpatient mortality for patients
receiving 3 forms of anticoagulation (UH, LMWH, and
lepirudin) was 37%. Six of the patients who died had
received UH therapy, whereas 1 had received LMWH. The
indications for UH administration were DVT prophylaxis
(n 5) and abdominal aortic aneurysm repair (n 1). The
remaining patient received LMWH after cardiac valve re-
placement. The lowest average platelet count in the 7
mortalities was 60,000/mm3 (1000/mm3–217,000/
mm3). Multisystem organ failure was the cause of death in
3 patients. Each of the following resulted in the death of 1
patient: heart valve thrombosis, respiratory failure, and
multiple deep venous thromboses of the portal and mesen-
teric system, and complications from ruptured abdominal
aortic aneurysm repair (mesenteric ischemia, renal failure).
Two episodes of arterial thrombosis and 1 episode of
bleeding occurred in this group.
The 31 complications directly associated with the pres-
ence of HAAb included 19 arterial thromboses (61%), 7
venous thromboses (23%), and 5 bleeding complications
(16%). The 19 arterial thromboses occurred in 6 patients
with thromboses of their arteriovenous fistulas, 5 with
lower extremity graft thromboses, 4 with native lower
extremity arterial thromboses, 2 with cerebrovascular acci-
dents, 1 with an iliac stent thrombosis, and 1 with a brachial
artery thrombosis. One of these patients also had a venous
thrombosis. Fifteen of these 19 patients had received UH
and 4 had received enoxaparin. The lowest average platelet
count was 168,000/mm3 (68,000/mm3–312,000/
mm3).
Seven patients had venous thromboembolic complica-
tions. Three had documented pulmonary emboli, 3 had
DVT, and 1 had thrombosis of a dialysis catheter. Four of
these patients had received UH, 2 had received enoxaparin,
and 1 had received both UH and LMWH. The lowest
average platelet count was 93,000/mm3 (46,000/mm3–
241,000/mm3).
The 5 bleeding complications included 2 cases of lower
gastrointestinal bleeding, 2 of upper gastrointestinal bleed-
ing, and 1 subarachnoid hemorrhage. All 5 patients had
received UH. The lowest average platelet count was
118,000/mm3 (1,000/mm3–379,000/mm3).
We have previously reported the morbidity and mortal-
ity associated with the diagnosis of HIT in our institution
for the years 1983, 1986, and 1997.4,5,10 The data from
the current study were compared with the previous reports
(Fig 2) in expectation of finding decreased morbidity and
mortality rates. To do this, we performed a normal approx-
imation of the binomial statistical analysis of the 3 previous
papers along with the current report (Table IV). The
morbidity in 1983 had a 95% confidence interval that did
not envelop the 95% confidence interval of that reported in
1986, 1997, and in this report. There was a significant
decrease in the morbidity between the 1983 to 1997 re-
ports. However, the current data demonstrate an increase
in morbidity that closely resembles that from 1986. A
statistically significant decline in mortality (95% confidence
interval) associated with HIT was found, with mortality
decreasing from 23% in 1983 to 12% in 1986 and to a low
of 1.1% in 1997. Unfortunately, our present data reveal a
statistically significant increase in mortality to 6.9%.
All patients were tested for HAAb against bovine and
porcine UH and enoxaparin and dalteparin (LMWH). The
results of HAAB testing are presented in Table V. Thirty
patients who received only heparin (bovine or porcine
origin) developed antibodies to all types of heparin tested,
including the 2 LMWH. Although no patient received
dalteparin, 48 samples aggregated platelets in the presence
of dalteparin. The platelet counts at the time of testing were
above 80,000 in the majority of patients.
Management of the HAAb-positive patients included
discontinuing the offending heparin in 95 patients, and
when continued anticoagulation was needed, the addition
of either a direct thrombin inhibitor (lepirudin  32),
enoxaparin (n 16), warfarin (n 15), or aspirin (n7 ).
Twenty-five patients did not require continued anticoagu-
lation and did not suffer adverse complications. The of-
fending agent was not discontinued in 7 patients (UH 3
and LMWH 4). These 7 patients had 1 arterial, 1 venous,
and 1 bleeding complication while receiving the sensitizing
heparin. One patient developed thrombosis of his arterio-
venous fistula but continued to receive heparin with dialysis
and maintained a normal platelet count. Another patient
developed a thrombosis of his dialysis catheter after receiv-
ing heparin. His platelet count also remained normal. One
patient developed upper gastrointestinal bleeding after re-
ceiving subcutaneous heparin for DVT prophylaxis. EGD
identified bleeding gastric ulcers with a positive H. pylori
biopsy. The platelet count fell to 32,000/mm3 before
returning to normal.
Five of the 7 patients who died required continued
anticoagulation. The sensitizing heparin was discontinued
in all patients. One of the 7 patients developed HAAb to
enoxaparin, which was discontinued and UH was utilized
for DVT prophylaxis. Two patients received lepirudin ther-
apy, 1 received warfarin therapy, and 1 received warfarin
and aspirin. Two patients did not require continued anti-
coagulation.
Table III. Admitting service
Service No. %
Vascular surgery 28 27.5%
General/trauma
surgery
21 20.5%
Cardiothoracic surgery 16 15.5%
Urology 5 5.0%
Orthopedic surgery 3 3.0%
Medicine/cardiology 19 18.5%
Nephrology 5 5.0%
Obstetrics 2 1.9%
Pediatrics 3 3.0%
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DISCUSSION
Heparin was discovered in 1916, introduced clinically
in 1935, and became firmly established as an excellent
agent for managing venous thromboembolism in 1960.4
Transient thrombocytopenia in association with the admin-
istration of heparin was identified in animals in 19429 and
in humans in 1962.11 Several authors reported a relation-
ship between heparin and arterial thrombosis.12,13 How-
ever, the relationship between HIT and thromboembolic
complications was not clearly identified until 1973.1
HIT presents in 2 forms. The more common type I occurs
in up to 30% of patients 1 to 3 days after the initiation of
heparin therapy. It is not immune-mediated and is thought to
occur in response to high doses of heparin causing platelet
binding to fibrinogen, leading to a mild thrombocytopenia. It
is characterized by a transient decrease in platelet count, with
clinically insignificant sequelae. The platelet count decline is
mild and resolves during continued heparin therapy.
Type II HIT, originally described in 1973, is an auto-
immune reaction that is often associated with life or limb-
Fig 2. Change in morbidity and mortality of HIT.
Table IV. Statistical analysis of morbidity and mortality
Year Patients
Morbidity Mortality
No. % 95% CI No. % 95% CI
1983 62 38 61.3 0.49, 0.73 14 22.6 0.13, 0.33
1986 169 38 22.5 0.16, 0.29 20 11.8 0.07, 0.17
1997 94 7 7.4 0.02, 0.13 1 1.1 0.01, 0.03
2003 102 31 30.4 0.21, 0.39 7 6.9 0.02, 0.18
Table V. Types of HAAb and heparin administered
Type of HAAb present
Type of heparin administered
Heparin (bovine and
porcine) Enoxaparin Dalteparin Unknown*
Beef, pork, Enoxaparin, Dalteparin 30 13 0 0
Beef, pork 12 2 0 4
Beef 6 0 0 1
Pork 4 2 0 1
Enoxaparin 2 1 0 0
Dalteparin Dalteparin 5 5 0 0
Enoxaparin, Dalteparin 1 0 0 0
Beef, pork, Dalteparin 7 2 0 1
Beef, pork, Enoxaparin 2 1 0 0
Pork, Dalteparin 3 2 0 0
Beef, Dalteparin 2 0 0 0
*Seven patients received an unknown type of heparin prior to admission.
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threatening arterial or venous thromboembolic complica-
tions. Type II HIT results from the development of HAAb
in response to heparin binding with circulating, platelet,
and endothelial-bound platelet factor 4 (PF4). These IgG,
IgM, and rarely IgA antibodies then bind strongly with the
heparin-PF4 complex. The immune complex reacts with
the platelet FcIIa receptors, leading to platelet activation
and thrombosis, rarely bleeding. HAAb also bind to the
same epitope on endothelial cells, resulting in endothelial
cell activation with the release of tissue factor (TF), which
can produce a hypercoagulable state.14
All patients who receive any type of heparin are at risk
for HIT. HIT has occurred after the administration of
porcine UH, beef UH, and LMWHs.15 No known patient
characteristics predict the development of this syndrome.
Patient sensitization is not related to the heparin dose or to
the route of administration. HIT can occur in patients who
receive small amounts of heparin (ie, heparin flushes for
intravenous catheters). HIT has been encountered in pa-
tients with heparin-coated pulmonary artery catheters and
heparin-bonded grafts.5 Patients of all ages, including new-
borns, are at risk for being sensitive to heparin.
Platelet counts should be obtained before the initiation
of heparin therapy in any patient and should be repeated at
least daily during the first 3 weeks of heparin administration
for all patients with prior exposure to heparin. Any patient
who receives heparin and has an unexplained decrease in
platelet count may have the HIT syndrome. We stop the
administration of heparin and test all patients with falling
platelet counts for HAAb Although thrombocytopenia has
been considered a prerequisite for thrombotic and hemor-
rhagic complications, HIT-related thromboses do occur in
the presence of normal platelet counts.5
The paradoxical thromboembolic complications asso-
ciated with HIT can be reduced in patients receiving hep-
arin if the characteristic thrombocytopenia, resistance to
anticoagulation with heparin, or new arterial or venous
thrombosis is recognized early and the administration of
the sensitizing heparin is promptly discontinued. Alterna-
tive anticoagulation regimens, including nonsensitizing he-
parins, direct thrombin inhibitors, or warfarin are offered
when clinically indicated.
It is not generally appreciated that the aggregation tests
can be negative, even though a patient has HAAb. If the
patient has sufficient circulating heparin to bind the anti-
bodies, the test may be negative. Our routine includes daily
repeat aggregation testing on patients with clinical signs of
HIT for 96 hours after all sources of heparin have been
eliminated. If the aggregation tests remain negative at 96
hours, the patient is considered not to have HIT and may
receive heparin if there is an indication for heparin therapy.
Not infrequently, a test that is negative on day 1 of testing
becomes positive on day 2, 3, or 4.
The incidence of HIT has been previously reported to
vary from 0.6% to 31% in patients receiving heparin.4 We
currently report an incidence of 0.92% (67 of 7256) for our
inpatients receiving UH, 1.6% (21 of 1339) for those
receiving LMWH and 0.4% (7 of 1753) for patients receiv-
ing both UH and LMWH. Seven HAAb patients received
heparin prior to admission. These data differ from those
reported by Warkentin and associates who reported the
development of HAAb in 2.2% of patients receiving
LMWH and 7.8% of those receiving UH.16 The overall
incidence of HAAb in our patients receiving any type or
combination of heparin was 0.99% (excluding the 7 pa-
tients that received an unknown heparin in other institu-
tions), a slight increase from the 0.6% incidence we re-
ported in 1983.4
HIT was identified in 0.3% of admissions to our hospi-
tal. In the United States, there were 32,639,620 acute care
admissions in the year 2000. Using these data, one can
estimate an occurrence of HIT in 97,919 acute care hospi-
tal admissions in the United States in the year 2000 (assum-
ing 30% of the admissions received some form of heparin).
We reported morbidity and mortality rates, in patients
with HIT, of 61% and 23%, respectively, in 62 patients in
1983.4 With early recognition and management, the mor-
bidity and mortality rates were reduced to 23% and 12%,
respectively, in 1987.10 A further reduction in morbidity
and mortality to 7.4% and 1.1% (in 100 HAAb positive
patients) was achieved in 1998.5 We are distressed to report
an unexpected increase in morbidity (19 arterial, 7 venous,
and 5 hemorrhagic events) and mortality to 30% and 6.9%,
respectively, in the current 102 patients. We attribute this
increase in morbidity and mortality to a decreased aware-
ness of the syndrome by new house staff and faculty and a
reduction in the frequency of obtaining platelet counts
during the first 3 weeks of heparin administration. If the
frequency of HIT in the United States approximates
98,000 cases per year, we estimate that annually 6762
patients will die and 29,400 patients will have complica-
tions from the administration of heparin.
Patients who develop HIT were predominately admit-
ted to a surgical service, with 48% being admitted to the
vascular and cardiothoracic surgical services during the
study period. We have previously reported the develop-
ment of HAAb in 21% of vascular surgery patients who
receive heparin during diagnostic and elective reconstruc-
tive vascular procedures.8
Two percent to 5% (1.3% of our patients)17 of open
heart surgery patients test positive for HAAb. Most patients
who undergo these types of surgery have had previous
exposure to heparin during diagnostic or therapeutic pro-
cedures. They may also have continued exposure to heparin
after surgery and seem to be particularly vulnerable to
development of HAAb, perhaps from excessive platelet
activation during cardiopulmonary bypass with the release
of increased amounts of PF4.
Seventeen patients receiving organ transplants tested
positive for HAAb. Our protocol is to test all heart trans-
plant patients on postoperative day 4 for the presence of
HAAb, whereas all kidney transplant recipients are tested
preoperatively. These guidelines were derived from litera-
ture documenting a higher than standard prevalence of
HAAb in patients undergoing organ transplantation.18,19
Within the study period, 24 heart transplants were per-
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formed. Overall, 42% of these patients developed HAAb.
During the same period, 106 kidney transplants were per-
formed, with 7% demonstrating HAAb preoperatively.
We currently test plasma from patients with suspected
HIT against porcine UH, bovine UH, enoxaparin, and
dalteparin. We reported in 1996 that 34% of HAAb-posi-
tive plasma from patients receiving UH also aggregated
platelets in the presence of enoxaparin and suggested that
the 66% of non-cross-reactive patients could receive enox-
aparin.20 In the current study, there was a 45% cross
reactivity between UH and LMWH. However, 55% of the
current reported patients were able to be treated with one
or more nonsensitizing heparins. Unfortunately, 42% our
HIT patients produced antibodies to all 4 types of heparin,
requiring an alternative form of anticoagulation. Overall,
15.6% of our HIT patients received enoxaparin for contin-
uous anticoagulation, 31.4% received lepirudin, 14.7% re-
ceived warfarin, and 6.9% received aspirin. When alternative
anticoagulation is required, we prefer direct thrombin in-
hibitors (DTI) for managing patients with HIT who re-
quire continuous rapid anticoagulation. We strongly rec-
ommend that patients with HIT not receive a sensitizing
heparin until they become HAAb negative. They should be
retested for HAAb after re-exposure to a sensitizing hepa-
rin.
Lepirudin (Refludan; Berlex Laboratories, Montville,
NJ) was the only DTI used during this study. Lepirudin, a
recombinant form of the medicinal leech salivary protein
hirudin, was approved by the U.S. Food and Drug Admin-
istration for use in patients with HIT in March 1998.
Lepirudin offers the patient adequate anticoagulation with
no risk of cross reaction with the patient’s HAAb. Lepiru-
din is excreted by the kidneys; the dose must be reduced in
patients with renal insufficiency. The dose for patients with
normal renal function is a bolus of 0.4 mg/kg followed by
a continuous infusion at 0.15 mg/kg/hr. The anticoagu-
lation effect is monitored by the activated partial thrombo-
plastin time (aPTT). Lepirudin has a circulating half-life of
1.3 hours in patients with normal renal function. The
half-life extends to 2 days in patients with advanced renal
failure. Although no antidote for lepirudin exists, the rela-
tively short half-life allows for correction of prolonged
aPTT’s, making lepirudin a safe and effective anticoagulant
for patients with HAAb.21
We have recently begun managing patients with HIT,
who require continued anticoagulation, with argatroban
(Glaxo SmithKline Pharmaceuticals, Philadelphia, Penn).
Argatroban is a synthetic direct thrombin inhibitor derived
from L-arginine. It is active against both free and clot-
bound thrombin. Argatroban undergoes hepatic metabo-
lism and excretion. The standard dose is 2 g/kg/min
intravenously, which is titrated to achieve an aPTT of 1.5 to
3.0 times the control. It is an irreversible inhibitor of
thrombin with a half-life of 40 to 50 minutes. There is no
specific antidote for argatroban, and administration should
be discontinued if hemorrhage occurs, or if the aPTT
becomes excessively prolonged. Argatroban also seems to
be a safe and effective agent for managing patients with
HAAb. All patients who require long-term anticoagulation
are converted to warfarin.
CONCLUSION
HIT remains a common iatrogenic disorder, which
occurs in 0.99% of inpatients receiving heparin. We esti-
mate that there were at least 97,919 cases of HIT in the
United States in the year 2000. Patients who have repeated
exposures to heparin during diagnostic or therapeutic pro-
cedures are at increased risk for acquiring the disorder.
LMWHs have not eliminated the occurrence of HIT. This
study found a prevalence of HAAb of 1.65% in patients
receiving LMWH and 0.92% in patients receiving UH. The
high degree of cross reactivity argues for more aggressive
use of alternative thrombin inhibition such as DTIs. De-
spite the term “heparin-induced thrombocytopenia,” the
degree of thrombocytopenia fails to correlate with either
the rate of antibody development or the severity of clinical
outcome. The early recognition of the manifestations of
HIT in conjunction with more frequent testing of patients
for HAAb has led to discontinuing the administration of
the sensitized heparin(s) with reductions of the morbidity
and mortality from a high of 61% and 23%, respectively, in
19834 to a low of 7.4% and 1.1%, respectively, in 1998.5
The increased morbidity and mortality, 30% and 6.9% in
this study, suggests a decreased awareness of the potential
complications of this disorder. If the 30% morbidity and
6.9% mortality were applied to the estimated 97,919 cases
of HIT, there would have been approximately 29,400
complications and 6762 deaths from HIT in the United
States in the year 2000.
Clinicians must recognize the symptoms of HIT and
stop the administration of the sensitizing heparin(s) before
patients suffer the sequelae of arterial or venous thrombo-
embolic or hemorrhagic events. Frequent platelet counts (a
low or falling count is suggestive of HIT) during heparin
administration and liberal testing for HAAb should lead to
earlier diagnoses, earlier cessation of sensitizing heparins,
and the use of alternative thrombin inhibitors. These steps
will, hopefully, lead to reductions in the morbidity and
mortality of HIT.
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